MIR23AHG and triple-negative breast carcinoma: Using MTT assay, we showed that Smyca knockdown enhanced the sensitivity of MDA-MB-231 cells to Dox and cisplatin (Fig. 7C), two commonly used chemotherapeutic drugs in treating triple-negative breast cancer (TNBC) [53].